Related Experiment Video
Updated: Jun 18, 2025

06:08
Transcranial Pulse Stimulation for Alzheimer's Patients
Published on: April 4, 2025
501
A transformer-based unified multimodal framework for Alzheimer's disease assessment
1Department of Big Data in Health Science, School of Public Health and Center of Clinical Big Data and Analytics of The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Computers in Biology and Medicine
|August 4, 2024
Summary
We developed AD-Transformer, a unified deep learning model integrating brain imaging, clinical, and genetic data for Alzheimer's disease (AD) diagnosis and Mild Cognitive Impairment (MCI) prediction.
Area of Science:
- Artificial Intelligence
- Neuroscience
- Medical Imaging
Background:
- Traditional deep learning for Alzheimer's disease (AD) uses separate methods for different data types.
- A unified approach is needed to analyze diverse data modalities for improved AD assessment.
Purpose of the Study:
- To introduce AD-Transformer, a novel unified deep learning model for Alzheimer's disease assessment.
- To integrate structural magnetic resonance imaging (sMRI), clinical, and genetic data for enhanced diagnostic accuracy.
Main Methods:
- Developed AD-Transformer, a transformer-based model integrating sMRI, clinical, and genetic data.
- Utilized Patch-CNN for image tokenization and linear projection for non-image data tokenization.
- Employed a transformer block to learn cross-modal representations from the ADNI database (1651 subjects).
Main Results:
- AD-Transformer achieved an average AUC of 0.993 for AD diagnosis and 0.845 for Mild Cognitive Impairment (MCI) conversion prediction.
- Outperformed traditional image-only and non-unified multimodal models in diagnostic accuracy.
- Demonstrated effective integration and analysis of multimodal data for AD assessment.
Conclusions:
- AD-Transformer offers a powerful, unified framework for AD diagnosis and MCI conversion prediction.
- The model effectively leverages multimodal data, paving the way for more precise clinical assessments.
- Presents a clinically adaptable strategy for utilizing diverse data in Alzheimer's disease research.
Related Concept Videos
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
Alzheimer's Disease: Treatment
171
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
171

